Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clemizole - Epygenix Therapeutics/University of California at San Fransisco

Next Previous
Drug Profile

Clemizole - Epygenix Therapeutics/University of California at San Fransisco

Alternative Names: EPX 100

Latest Information Update: 21 Jan 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of California at San Francisco
  • Developer Epygenix Therapeutics
  • Class Antiallergics; Antiepileptic drugs; Antihistamines; Benzimidazoles; Pyrrolidines; Small molecules
  • Mechanism of Action Hepatitis C virus NS4 protein inhibitors; Histamine H1 receptor antagonists; Serotonin receptor agonists; Serotonin receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Epilepsy; Dravet syndrome; Lennox-Gastaut syndrome
  • New Molecular Entity No

Highest Development Phases

  • Phase III Lennox-Gastaut syndrome
  • Phase II Dravet syndrome
  • Phase I Epilepsy

Most Recent Events

  • 15 Jan 2025 Phase-III clinical trials in Lennox-Gastaut syndrome (PO)
  • 31 Dec 2024 Phase-III clinical trials in Lennox-Gastaut syndrome (In children, In adolescents, In adults) in USA (PO), before December 2025 (NCT05066217)
  • 29 Oct 2024 Harmony Biosciences plans a phase III registration trial for Lennox-Gastaut syndrome in 2024

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top